Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 7/20 | 0.39 |
| ▸ | RAB9A | P51151 | 7/20 | 0.39 |
| ▸ | HTT | P42858 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GALR3 | O60755 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982718 | 1.00 | TBXAS1 (0.48) | TBXAS1NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL5982929 | 0.98 | TBXAS1 (0.46) | TBXAS1NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL5982105 | 0.92 | — | — | |
| SCHEMBL5981645 | 0.83 | — | — | |
| SCHEMBL5983050 | 0.82 | TBXAS1 (0.33) | TBXAS1 | |
| SCHEMBL5982238 | 0.78 | HRH4 (0.31) | KDM4EALDH1A1 | |
| SCHEMBL5983204 | 0.78 | KDM4E (0.35) | NPSR1LMNAKDM4EALDH1A1 | |
| SCHEMBL5981726 | 0.77 | ALDH1A1 (0.38) | TBXAS1LMNAPOLBALDH1A1TP53 | |
| SCHEMBL5982818 | 0.76 | CYP2D6 (0.35) | SMN1; SMN2NPSR1LMNAMAPTKDM4E | |
| SCHEMBL5982840 | 0.76 | DGKA (0.45) | MAPK1LMNAMAPTALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | SCOTT ROBERT A D (US) | 2011-12-29 | — | — | US | disclosed |
| EP-1931355-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | Atherogenics, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| WO-2007044726-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | ATHEROGENICS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1446113-A4 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS INC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1446113-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | Atherogenics, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2001034618-A2 | SYNTHESIS OF 2'-DEOXY-L-NUCLEOSIDES | PHARMASSET LIMITED (US) | 2001-05-17 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0560330-A2 | Substituted benzimidazolyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0556789-A2 | Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-25 | — | — | EP | disclosed |
| EP-0552765-A1 | Benzimidazoles, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | TBXAS1 3262/4885NPC1 1612/4885RAB9A 2645/4885 |
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | PLAT, F2, TFPI | TBXAS1 43/4885NPC1 2062/4885RAB9A 974/4885 |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | PLAT, F2, TFPI | TBXAS1 43/4885NPC1 2062/4885RAB9A 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.